Parkinson's disease

Keywords

Pars compacta, Medicine, Disease, Parkinson's disease, Dopamine

References

• Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?Kenji Kosaka, Masahiro Yoshimura, Ken‐ichi Ikeda — 1984
• Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies.Caroline M. Tanner — 2003
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International WorkshopIan G. McKeith — 2006
• Morphogenesis of Lewy Bodies: Dissimilar Incorporation of α‐Synuclein, Ubiquitin, and p62Erkki Kuusisto, Laura Parkkinen, Irina Alafuzoff — 2003
• DATATOP: A decade of neuroprotective inquiryIra Shoulson, Parkinson Study Group — 1998
• Levodopa and the progression of Parkinson's disease.The Parkinson Study Group — 2004
• The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregatesKoichi Wakabayashi, Kunikazu Tanji, Fumiaki Mori — 2007
• Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriersPeter P. Pramstaller, Michael G. Schlossmacher, Thomas S. Jacques — 2005
• Life‐threatening parkinsonism induced by kava‐kavaElena Meseguer, Rocio Taboada, Vicenta Sánchez — 2002
• Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PDA. Iranzo, Joan Santamaría, David B. Rye — 2005
• Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosisJan Zijlmans, Susan E. Daniel, Andrew Hughes — 2004
• Cognitive status correlates with neuropathologic stage in Parkinson diseaseHeiko Braak, Udo Rüb, Ernst N.H. Jansen Steur — 2005
• Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease: Practical Aspects and Outcome of Motor and Non-motor ComplicationsKarla Eggert, Christoph Schrader, Michaela Hahn — 2008
• A common LRRK2 mutation in idiopathic Parkinson's disease.William P. Gilks, Patrick M. Abou‐Sleiman, Sonia Gandhi — 2005
• New practice parameters in Parkinson's diseaseJanis M. Miyasaki — 2006
• The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.Philippe Damier, Étienne C. Hirsch, Yves Agid — 1999
• Update in the epidemiology of Parkinson's diseaseAlexis Elbaz, Frédéric Moisan — 2008
• Evidence‐based analysis of physical therapy in Parkinson's disease with recommendations for practice and researchS.H.J. Keus, Bastiaan R. Bloem, Erik Hendriks — 2007
• Prevalence of Parkinson's disease in the elderlyM. C. de Rijk, Monique M.B. Breteler, G.A. Graveland — 1995
• Olfaction and Parkinson's syndromes: its role in differential diagnosisRegina Katzenschlager, Andrew J. Lees — 2004

Cited by

• Etiopathogenesis of vitiligo in the light of our studies.T Chorazak, E Rzempołuch — 1968
• A new anticoagulant medication in cardiac valve replacement.Masahiko Washio, I Sakashita, Chiharu Nakamura — 1978
• New animal models of Parkinson's diseaseBenjamin Dehay, Erwan Bézard — 2011
• The fine structure of Brunn's nests in human bladder urothelium.S P Jost, J. A. Gosling, J. S. Dixon — 1990
• [Significance of inferior ST segment changes in acute anterior myocardial infarction--relationship between the distribution of left anterior descending artery and concomitant ischemia of the inferior wall].H. Miki, Yasuhiro Nakagawa, Y Satou — 1990
• [Treatment of anterior hypospadias. Place of balanoplasty].S Juskiéwenski, P Vaysse, J. Guitard — 1983
• Factors associated with motor complications in Parkinson's diseaseLiis Kadastik‐Eerme, Nele Taba, Toomas Asser — 2017
• Des faits Ë expliquer aux faits explicateursA. Joly — 1996
• [Influenza in 1998].Krzysztof Kuszewski, Lidia B. Brydak — 2000
• Maladie de Parkinson et réanimation : des problèmes spécifiques ?C. Gombert, Yann Nadjar, David Grabli — 2013
• Clinical and pathological features of Parkinson's disease.Susanne A. Schneider, José Á. Obeso — 2015
• Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.K. A. Jellinger — 2011
• Role of Wnt Signaling in Central Nervous System InjuryCatherine Lambert, Pedro Cisternas, Nibaldo C. Inestrosa — 2015
• Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson’s DiseaseMichael J. Hurley, Pascal F. Durrenberger, Steve Gentleman — 2015
• Highly sensitive isotope-dilution liquid-chromatography–electrospray ionization–tandem-mass spectrometry approach to study the drug-mediated modulation of dopamine and serotonin levels in Caenorhabditis elegansFabian Schumacher, Sudipta Chakraborty, Burkhard Kleuser — 2015
• Normalization of Overexpressed α-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference.Masaki Takahashi, Mari Suzuki, Masashi Fukuoka — 2015
• PREDICTING THE EQ-5D FROM THE PARKINSON'S DISEASE QUESTIONNAIRE PDQ-8 USING MULTI-DIMENSIONAL BAYESIAN NETWORK CLASSIFIERSHanen Borchani, Concha Bielza, Pablo Martínez‐Martín — 2014
• Protection effect of piperine and piperlonguminine from Piper longum L. alkaloids against rotenone-induced neuronal injury.Hao Wang, Jia Liu, Ge Gao — 2016
• The temporary and accumulated effects of transcranial direct current stimulation for the treatment of advanced Parkinson’s disease monkeysHao Li, Xiaoguang Lei, Ting Yan — 2015
• Alpha-linolenic acid suppresses dopaminergic neurodegeneration induced by 6-OHDA in C. elegans.Shivaiah Shashikumar, H. Pradeep, Chinnu Salim — 2015

Related papers

• [Morphological parameters of the heterogeneity of the substantia nigra in elderly men and women].V N Salkov, Р. М. Худоерков, Д. Н. Воронков — 2015
• Quantitative research on FA value of substantia nigra pars compacta in early Parkinson′s diseaseChen Yan-shen — 2014
• Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta.Nina Eriksen, Anette Kirstine Stark, Bente Pakkenberg — 2009
• Threedimensional reconstruction of substantia nigra pars compacta of human brainД. Н. Воронков, V N Salkov, Р. М. Худоерков — 2018
• Threedimensional reconstruction of substantia nigra pars compacta of human brainД. Н. Воронков, V N Salkov, Р. М. Худоерков — 2018
• Regulation of c-Ret, GFRalpha1, and GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease.Sònia Marco, Josep Saura, Esther Pérez‐Navarro — 2002
• A comparative study of FA and T2 *values of the substantia nigra pars compacta for diagnosis of early Parkinson′s diseaseChen Yan-shen — 2014
• Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageingMa ., Röytt, Collan — 1999
• The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.Philippe Damier, Étienne C. Hirsch, Yves Agid — 1999